There's some great news from today's Johnson & Johnson one-dose coronavirus vaccine trial results, explains Yale School of Public Health & yaleschoolofmed immunologist Akiko Iwasaki. . . . . Image description: tweet from Prof. Akiko Iwasaki that says "A single-shot J&J Janssen COVID19 vaccine phase 3 results summarized in one table. Great news! Imagine being 💯 protected from death 28 days after a single shot, and 💯 protected from severe disease after 49 days - against all variants." and a table showing the Efficacy of Johnson & Johnson Single-Shot Jansen COVID-19 Vaccine Phase 3 ENSEMBLE Trial. It shows the vaccine is 72% effective for moderate & severe disease after 28 days in the U.S., 66% in Latin American and 57% in South Africa (95% B.1.351 variant). For all variants, it's 85% effective for severe disease and 100% effective for death after 28 days and 100% effective for severe disease after 49 days. #JohnsonAndJohnson #Vaccines #CovidVaccines #CovidNews #ThisIsPublicHealth #G...